Crossmark

Clinical and event-based outcomes of patients with mucopolysaccharidosis VI receiving enzyme replacement therapy in Turkey: a case series

Published Online: 2021-10-19

Published Print: 2021-12

Authors

İnci, Aslı

Okur, İlyas

Tümer, Leyla

Biberoğlu, Gürsel

Öktem, Murat

Ezgü, Fatih https://orcid.org/0000-0001-9497-3118
Funding

Funding for this research was provided by:

biomarin pharmaceutical
License Information

Text and Data Mining valid from 2021-10-19

Version of Record valid from 2021-10-19
More Information

Article History

Received: 29 June 2021

Accepted: 30 September 2021

First Online: 19 October 2021

Declarations

:

: The study was approved by the Gazi University Faculty of Medicine Ethics Committee; approval date: April 13 2020; approval number 262. All patients provided consent to participate in the study.

: All patients provided consent to publish clinical data.

: The authors report no competing interests.

Document is current